Sökresultat

MultiPark’s new special interest groups (SIGs) address essential scientific and technological needs and provide opportunities for professional development and network formation to our young scientists. One of them focus on molecular signaling. Lautaro Belfiori is the convening person. He shares with us how they plan to work with questions related to molecular signaling. Can you shortly describe th

https://www.multipark.lu.se/article/molecular-signaling-neurodegenerative-disorders-special-interest-group - 2025-10-01

Keivan Javanshiri’s Ph.D. project explores cardiac and vascular pathologies in Lewy body dementia and Alzheimer's disease. January 20, he defends his thesis. Here, he shares the most important findings and why sudden cardiac arrest is a common cause of death in patients with Lewy body disease. Tell us about your research! “My research focuses on cognitive disorders, which you may envision like a t

https://www.multipark.lu.se/article/cognitive-disease-beyond-brain-phd-interview-keivan-javanshiri - 2025-10-01

We ended the MultiPark year in December as we started it in January: with a MultiPark Retreat! The December retreat was our first big meeting IRL after the pandemic, and it turned out to be a much appreciated event. Thank you to all participants, and thank you once again to the retreat organizing committee for doing such a great job! 2022 was a year of “reopening”. Like a butterfly spreads its win

https://www.multipark.lu.se/article/multipark-closing-circle-2022-and-looking-forward-2023 - 2025-10-01

Katrine Skovgård’s Ph.D. project sheds light on the dysfunctions in the brain through which dopaminergic pharmacotherapies for Parkinson’s disease affect motor behaviors. January 19, she defends her thesis. She explains how better experimental models might improve future translational research on dyskinesia. You presented your research at the MultiPark Café recently. But for those who could not at

https://www.multipark.lu.se/article/why-dopamine-receptor-type-matters-phd-interview-katrine-skovgard - 2025-10-01

At the end of October 2022, the Swedish Medical Products Agency gave the go-ahead for a clinical trial of the stem cell-based therapy STEM-PD for the treatment of Parkinson’s disease. The cells, generated from embryonic stem cells, have been in development for several years and will now be transplanted into patients with Parkinson’s to replace nerve cells lost due to the disease. The clinical tria

https://www.multipark.lu.se/article/nerve-cells-could-transform-treatment-parkinsons - 2025-10-01

Huntington's disease is known as the "dance disease" due to the patient's characteristic motor symptoms. However, Elna Dickson's Ph.D. project shows that the disease also leads to pathological changes outside the brain. February 17, she defends her thesis about metabolic alterations in Huntington's disease. Now, she shares perspectives on her research journey. Tell us about your research! "Hunting

https://www.multipark.lu.se/article/huntingtons-metabolic-dysfunctions-phd-interview-elna-dickson - 2025-10-01

The aggregation of the protein Amyloid-beta (Abeta) into plaques outside the nerve cells has been recognized in patients with Alzheimer’s disease since 1905. But eliminating the plaques has not helped patients so far. Still, Tomas Roos thinks that Abeta matters, but we may need to focus on the aggregates elsewhere. On February 17, he defends his thesis about prion-like proteins in neurodegeneratio

https://www.multipark.lu.se/article/does-alzheimers-disease-start-inside-neurons-phd-interview-tomas-roos - 2025-10-01

On 13th of February, a transplant of stem cell-derived nerve cells was administered to a person with Parkinson’s at Skåne University Hospital, Sweden. The product has been developed by Lund University and it is now being tested in patients for the first time. The transplantation product is generated from embryonic stem cells and functions to replace the dopamine nerve cells which are lost in the p

https://www.multipark.lu.se/article/first-patient-receives-milestone-stem-cell-based-transplant-parkinsons-disease - 2025-10-01

The boundaries between biology and technology are becoming blurred. Researchers at Linköping, Lund, and Gothenburg universities in Sweden have successfully grown electrodes in living tissue using the body’s molecules as triggers. The result, published in the journal Science, paves the way for the formation of fully integrated electronic circuits in living organisms. This news was initially publish

https://www.multipark.lu.se/article/electrodes-grown-brain - 2025-10-01

Kajsa Brolin explores how our genes and environment affect the risk of developing Parkinson’s disease. March 27, she defends her Ph.D. project partly based on MultiPark’s biobank sample collection. Here, she tells about the newly discovered genetic risk factor that might be specific to people in the southern part of Sweden. And is coffee really protective? Tell us about your research! “My research

https://www.multipark.lu.se/article/genes-and-environment-pd-phd-interview-kajsa-brolin - 2025-10-01

After a decade of protocol development and preparations, MultiPark researchers have finally launched the clinical trial. Recently, dopamine-producing cells generated from embryonic stem cells were transplanted into the first Parkinson's patient at Skåne University Hospital. During the autumn 2022, the Swedish MPA (Läkemedelsverket) approved the clinical STEM-PD study. Several of MultiParks PIs hav

https://www.multipark.lu.se/article/stem-pd-bench-bedside-story-multipark-researchers-0 - 2025-10-01

Looking for the next step in your career? In need of some scientific inspiration? Or are you just curious about what MultiPark´s senior researchers are doing and their professional journey? Listen to MultiPark’s new podcast series “Meet our scientists”! In a newly launched podcast, young MultiPark researchers interview our research group leaders about their academic journey and main scientific foc

https://www.multipark.lu.se/article/meet-our-scientists-new-podcast-young-multipark-researchers - 2025-10-01

In the early 1950s, no one knew what caused Parkinson's disease. Then, Arvid Carlsson's discovery of dopamine opened the door to world-leading transplantations for Parkinson's patients. Thanks to the pioneering basic research at MultiPark, stemcell-derived neural cells can now be tested in a clinical trial for the first time. In Parkinson's disease, the nerve cells in an area of the brain that con

https://www.multipark.lu.se/article/world-parkinsons-day-transplantations-parkinsons-disease-time-travel - 2025-10-01

Genetics are one of the keys to understanding neurodegenerative disease. That is why MultiPark researchers with expertise in genetics gather across research groups. Genetics of neurodegenerative diseases is a new special interest group (SIG) addressing scientific and technological needs to unravel the genetics behind diseases such as Parkinson’s and Alzheimer’s. Andreas Puschmann tells about how h

https://www.multipark.lu.se/article/genetics-neurodegenerative-diseases-special-interest-group - 2025-10-01

Three researchers at Lund University, all with a long list of significant research credentials, have been awarded the ERC Advanced Grant worth EUR 2.5 million each to further develop and advance their research projects. Two of them are MultiPark research leaders. They do research on chaperone proteins’ function in neurodegenerative diseases and blood tests for rapid screening of drugs in the treat

https://www.multipark.lu.se/article/double-success-multipark-research-groups-prestigious-eu-grant-round - 2025-10-01

Several Nobel laureates, renowned scientists, and successful biotech entrepreneurs are coming to Lund in May to participate in the Lund Spring Symposium, an international pharmaceutical symposium sponsored by MultiPark. Sarah Tabrizi, a high profile Huntington researcher, and some of MultiPark's own researchers will speak. Medications are the physician's primary tool when treating their patients,

https://www.multipark.lu.se/article/superstars-coming-lund-pharmaceutical-symposium-sponsored-multipark - 2025-10-01

Forskare vid Lunds universitet har i samarbete med kollegor i tyska Dresden, tagit fram ett sätt att kombinera benersättningsmedel och läkemedel med syftet att återbilda ben och läka allvarliga frakturer i exempelvis lår eller underben. Studien, som publiceras i den vetenskapliga tidskriften Science Advances, är gjord på råttor men forskarna menar att metoden i olika kombinationer snart blir klini

https://www.medicin.lu.se/artikel/ny-metod-laker-skelettskador-med-konstgjort-ben - 2025-10-01

Framstående insatser inom reumatologi och epidemiologi samt logopedi och audiologi lyfts fram när Medicinska fakulteten utser två nya hedersdoktorer för 2021. Tuhina Neogi och Laurence B. Leonard kommer att promoveras i Lunds domkyrka den 27 maj 2021. Förebild som ledareProfessor Tuhina Neogi är verksam vid Boston University School of Medicine, USA, inom området reumatologi. Hon är en världsledand

https://www.medicin.lu.se/artikel/nya-hedersdoktorer-vid-medicinska-fakulteten-2021 - 2025-10-01

Forskare publicerar nya rön om validerade biomarkörer för individens risk att utveckla Alzheimers sjukdom. Med en modell som kombinerar nivåerna av två specifika proteiner i blodet hos personer med lättare minnessvårigheter kan forskarna förutsäga risken att utveckla alzheimerdemens på individnivå. Forskarna har även utvecklat en onlinetjänst, en app där läkaren skriver in patientens undersöknings

https://www.medicin.lu.se/artikel/biomarkorer-och-app-forutsager-individers-risk-utveckla-alzheimer - 2025-10-01

João Duarte söker kopplingar mellan kognitiv försämring och diabetes. ”Våra fynd kan en dag bidra till utvecklingen av behandling av metabola eller neurologiska sjukdomar”. João Duarte är en av forskarna på Wallenberg centrum för molekylär medicinsk forskning vid Lunds universitet (WCMM LU). Under hösten 2020 presenterar vi varje vecka en forskare verksam vid centrumet. WCMM vid Lunds universitet

https://www.medicin.lu.se/artikel/mot-veckans-wallenbergforskare-joao-duarte - 2025-10-01